Skip to main content

Table 6 Management of the patient with ILD/IPF

From: Diagnosis and management of interstitial lung disease

▪ Establish a partnership with the patient to provide a patient-centered, personalized medicine care plan ▪ Provide supplemental oxygen if indicated (keep SpO2 ≥90%)
▪ Provide patients with:   · During exertion
  · Nocturnal during sleep
 • Useful information concerning   the nature of their disease   and its prognosis   · Continuous if indicated
 • Treatment options   accompanied by   thoughtful counseling ▪ Detect and treat co-morbidities and complications:
  · Enrollment in clinical trials   · Gastroesophageal reflux    disease
  · Off-label therapies    (e.g. corticosteroids,    cytoxic drugs, other agents)   · Cardiovascular disease
  · Lung transplantation   · Drug toxicity (if treated)
  · Best supportive care   · Sleep-disordered breathing
▪ Use disease-specific monitoring (for prognostication and treatment decisions)   · Secondary pulmonary    hypertension
  · Pulmonary function testing    (FVC, DLCO, 6-MWT)   · Metabolic bone disease    (osteopenia, osteoporosis)
  · Thoracic imaging   · Anemia
  · Dyspnea score   · Anxiety & depression
▪ Pulmonary rehabilitation (optimal exercise program, patient education) ▪ Maintain ideal body-mass index (weight reduction if obese, improved nutrition if cachectic)
▪ Vaccinations (pneumococcal vaccine, seasonal influenza, others as indicated)
  1. DLCO = diffusion capacity of the lung for CO; FVC = forced vital capacity; 6-MWT = six-minute walk test; SpO2 = oxyhemoglobin percent saturation.